BioNTech joins Biologics Pharma Innovation Programme Singapore consortium

The consortium aims to grow Singapore’s capabilities in biologics manufacturing.

The Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium welcomed global immunotherapy company BioNTech to its roster of members.

The consortium, led by A*STAR, aims to increase productivity and sustainability in biologics manufacturing, transforming the existing base of biologics production in Singapore. 

The consortium focuses on biologics products, including recombinant therapeutic proteins and vaccines, which were vital during the COVID-19 pandemic. 

BioPIPS consortium includes GSK, Sanofi, Nanyang Technological University, Singapore (NTU), NTUitive, National University of Singapore (NUS), and Singapore Institute of Technology (SIT).

Consortium members inked a Memorandum of Understanding (MoU) in 2022, which enabled discussions on manufacturing challenges for potential research projects.